SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon's President and Chief Executive Officer, will present at the 2007 BIO Investor Forum on Thursday, October 11, 2007, at 9:30 a.m. PDT at the Palace Hotel in San Francisco. The presentation will take place in the Pacific Heights room.
About Cerimon Pharmaceuticals
Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.
Cerimon currently has two drugs in development. Simulect(R) (basiliximab)entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in the first quarter of 2007, and the Company has initiated a Phase I study of a topical patch formulation of diclofenac sodium. This study will rapidly be followed by late-stage efficacy and safety studies in patients with acute musculoskeletal pain.
Cerimon is well financed, having closed a $70 million Series A financing in late 2005 with the premier investors MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.
For more information on Cerimon, please visit the Company's website at http://www.cerimon.com/.
CONTACT: Jim Welch, Chief Financial Officer of Cerimon Pharmaceuticals,
+1-650-827-4000, email@example.com; or Media, Justin Jackson,
firstname.lastname@example.org, or Jason Farber, email@example.com; or Investors,
Juliane Snowden, firstname.lastname@example.org, or Nicki Kahner,
email@example.com, all of Burns McClellan, Inc., +1-212-213-0006
Web site: http://www.cerimon.com/